Today: 7 February 2026
Subscribe
Browse Category

Healthcare News 3 January 2026 - 9 January 2026

Why iRhythm stock is sliding today as Wall Street looks to JPM Healthcare Conference

Why iRhythm stock is sliding today as Wall Street looks to JPM Healthcare Conference

New York, Jan 9, 2026, 15:54 EST — Regular session Shares of iRhythm Technologies (IRTC.O) fell 3.9% to $181.95 on Friday, after swinging between $190.16 and $179.61 in the session. The stock ended Thursday at $189.25. The drop left iRhythm behind a broader advance in U.S. equities, with S&P 500 and Nasdaq-tracking funds up about 0.8% and 1.1%, respectively. That gap matters because iRhythm trades like a growth stock — sensitive to rate moves and risk appetite — and those currents can swamp stock-specific news for stretches. A Labor Department report showed nonfarm payrolls — a broad count of jobs
9 January 2026
·····
Why Immunome stock is up today: IMNM jumps 7% as biotech firms up and JPM conference looms

Why Immunome stock is up today: IMNM jumps 7% as biotech firms up and JPM conference looms

New York, January 9, 2026, 13:01 EST — Regular session Immunome, Inc. shares jumped on Friday, outpacing a firmer biotech tape. The Nasdaq-listed stock (IMNM) was up 7.4% at $21.97, after trading between $20.71 and $22.00. The move keeps attention on Immunome’s lead drug, varegacestat, being developed for desmoid tumors — non-cancerous growths in connective tissue that can still be painful and hard to treat. The company has said it plans to file a New Drug Application (NDA) with the U.S. Food and Drug Administration in the second quarter of 2026; an NDA is the formal request for approval to
9 January 2026
·······
Amazon Pharmacy adds Wegovy pill at $149 cash price, putting Novo Nordisk’s NVO stock back in play

Amazon Pharmacy adds Wegovy pill at $149 cash price, putting Novo Nordisk’s NVO stock back in play

NEW YORK, Jan 9, 2026, 10:12 (EST) Amazon Pharmacy said on Friday it now offers Novo Nordisk’s Wegovy weight-loss pill through insurance plans and a cash-pay option, with uninsured customers paying from $149 a month and some commercially insured customers paying $25 for a one-month supply. Amazon said it will add the pill to its pharmacy kiosks in the coming weeks and is working with telehealth firms including WeightWatchers, Wheel and 9amHealth; Novo has said the pill will also be available through CVS, Costco and other telehealth services such as Ro, LifeMD and GoodRx. The U.S. FDA approved the once-daily
9 January 2026
·····
Amazon stock dips as Amazon Pharmacy adds Novo Nordisk’s Wegovy pill, with $25 insured pricing

Amazon stock dips as Amazon Pharmacy adds Novo Nordisk’s Wegovy pill, with $25 insured pricing

NEW YORK, Jan 9, 2026, 09:35 EST — Regular session Amazon Pharmacy said it now offers Novo Nordisk’s Wegovy pill through insurance plans and a cash-pay option, widening its push into prescription drugs as demand for weight-loss treatments spreads beyond injections. Eligible customers with commercial insurance may pay as little as $25 for a one-month supply, while customers without insurance can buy the pill starting at $149 per month; U.S. regulators approved the 25-milligram semaglutide pill in December, the company said. Amazon.com shares were down 0.7% at $244.58 in early New York trade. The rollout matters because Amazon is trying
9 January 2026
······
CSL Limited (ASX:CSL) shares jump 2.6% as healthcare bounces; three dates investors circle

CSL Limited (ASX:CSL) shares jump 2.6% as healthcare bounces; three dates investors circle

SYDNEY, Jan 8, 2026, 16:50 AEDT — Market closed CSL Limited shares closed up 2.6% at A$174.45 on Thursday, after trading between A$172.03 and A$175.10. The stock is still down about 39% over the past year and has ranged between roughly A$168 and A$289 over that period. Investing.com The gain helped steady Australia’s heavyweight healthcare name as the S&P/ASX 200 ended up 0.3% at 8,720. The Australian dollar was about 0.3% lower at 67.02 U.S. cents in late trade. ABC Part of the lift came from a broader bounce in battered pockets of the market, with healthcare up about 1.2%
8 January 2026
·····
Apellis stock jumps nearly 8% as investors look to JPM healthcare update

Apellis stock jumps nearly 8% as investors look to JPM healthcare update

New York, Jan 7, 2026, 12:14 PM EST — Regular session Apellis Pharmaceuticals shares rose nearly 8% on Wednesday, outperforming the broader market as traders positioned ahead of the company’s scheduled appearance at next week’s J.P. Morgan Healthcare Conference. investors.apellis.com The Waltham, Massachusetts-based drugmaker said on Monday it will present on Jan. 12 at 11:15 a.m. PT, with a live webcast posted to its investor site and a replay available afterward. Big healthcare conferences often bring fresh guidance, new trial details or partnering chatter — and the tape tends to price that in early. investors.apellis.com Apellis was last up $1.91
7 January 2026
·····
Intuitive Surgical stock jumps as investors eye JPM healthcare conference and Jan. 22 earnings

Intuitive Surgical stock jumps as investors eye JPM healthcare conference and Jan. 22 earnings

New York, January 7, 2026, 04:55 ET — Premarket Intuitive Surgical, Inc. (ISRG.O) shares rose 4.6% to close at $592.85 on Tuesday and were last up about 0.4% in after-hours trading. MarketWatch The move matters now because January is a key checkpoint for medical device stocks, with investors looking for early-year signals on hospital spending and procedure demand. For Intuitive, even small changes in tone around system placements and recurring instrument sales can quickly shift expectations. The stock is near the top of its 52-week range and carries a rich valuation, which can amplify swings around news. Nasdaq data show
7 January 2026
·····
Johnson & Johnson stock in focus after Tecvayli-Darzalex filing, lupus drug data

Johnson & Johnson stock in focus after Tecvayli-Darzalex filing, lupus drug data

New York, January 6, 2026, 21:28 EST — Market closed Johnson & Johnson shares closed up 0.23% on Tuesday after the company announced fresh clinical and regulatory updates across oncology and immunology. The developments matter now because investors are looking for durable growth drivers heading into quarterly results later this month, when management is expected to frame demand trends and the pipeline into 2026. Late-stage filings and mid-stage readouts can move the outlook for a drugmaker even when the stock barely budges on the day, especially for a large-cap name where incremental product wins tend to show up in guidance
7 January 2026
···
UnitedHealth stock jumps on TPG-Optum UK deal report as Jan. 27 earnings loom

UnitedHealth stock jumps on TPG-Optum UK deal report as Jan. 27 earnings loom

New York, January 6, 2026, 11:46 (EST) — Regular session UnitedHealth Group shares climbed on Tuesday after a report said buyout firm TPG was closing in on a deal for the insurer’s Optum UK unit, a move investors read as another step in reshaping its health-services portfolio. The stock was up 2.1% at $349.25 by 11:30 a.m. ET. Reuters The timing matters because UnitedHealth is nearing a key reset for investors: its full-year 2025 results and 2026 guidance due later this month. The company has said it will report on Jan. 27 before the market opens and host an 8
6 January 2026
····
Healthcare stock Ironwood jumps 27% on Linzess price cut and 2026 profit outlook

Healthcare stock Ironwood jumps 27% on Linzess price cut and 2026 profit outlook

NEW YORK, Jan 4, 2026, 13:54 ET — Market closed Ironwood Pharmaceuticals shares jumped 26.7% on Friday to close at $4.27, outpacing the broader healthcare stock complex after the company laid out a sharply higher 2026 outlook tied to its Linzess constipation drug. Investing The move matters because Ironwood is trying to prove it can generate steady cash flow from a single commercial asset while it works through a strategic review and prepares a key late-stage study for its pipeline drug apraglutide. SEC It also lands at a sensitive moment for U.S. drug pricing, where headline list-price cuts do not
4 January 2026
·····
UnitedHealth stock starts 2026 higher — here’s what matters before Monday’s open

UnitedHealth stock starts 2026 higher — here’s what matters before Monday’s open

NEW YORK, Jan 4, 2026, 10:47 ET — Market closed UnitedHealth Group Incorporated shares rose 1.91% on Friday to close at $336.40, as U.S. stocks started 2026 with modest gains. Managed-care peers also advanced, with Humana up 3.26% and Elevance Health up 1.06%, while the S&P 500 added 0.19% and the Dow climbed 0.66%. U.S. markets are closed on Sunday and reopen Monday. MarketWatch The next major catalyst comes Jan. 27, when UnitedHealth is scheduled to report full-year 2025 financial results and provide 2026 financial guidance before the market opens. The company said it will host a teleconference at 8:00
4 January 2026
·····
Healthcare Stocks Today: XLV edges up as drugmakers raise U.S. list prices on 350 medicines

Healthcare Stocks Today: XLV edges up as drugmakers raise U.S. list prices on 350 medicines

NEW YORK, Jan 3, 2026, 13:21 ET — Market closed Drugmakers are lifting U.S. list prices on hundreds of medicines as 2026 begins, putting drug-pricing politics back in focus for healthcare investors. The sector finished higher in Friday’s session, the last U.S. trading day before the weekend. Drugmakers plan to raise U.S. prices on at least 350 branded medicines for 2026, including vaccines for COVID-19, RSV and shingles, as well as Pfizer’s cancer drug Ibrance, Reuters reported, citing data from healthcare research firm 3 Axis Advisors. The median list-price increase is about 4%, and the changes do not reflect rebates
3 January 2026
·······
1 … 4 5 6 7 8 … 13

Stock Market Today

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 07.02.2026

7 February 2026
LIVEMarkets rolling coverageStarted: February 7, 2026, 12:00 AM ESTUpdated: February 7, 2026, 12:31 AM EST Dollar Dips as Stocks Rally and US Data Influences Fed Rate Expectations February 7, 2026, 12:18 AM EST. The **dollar index** fell 0.17%, pressured by a rebound in equity markets reducing demand for the safe-haven currency. Weaker-than-expected U.S. labor market data raised the odds of a Fed rate cut to 18% for March, though consumer sentiment improved to a six-month high, limiting losses. Hawkish comments from Atlanta Fed's Raphael Bostic emphasized maintaining restrictive monetary policy. The dollar faces medium-term weakness amid expectations for rate cuts
Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

7 February 2026
Seagate shares rose 5.9% to $429.32 Friday after Citigroup raised its price target to $480 and reiterated a buy rating. The gain ended a two-day slide but left the stock 6.6% below its Feb. 3 high. CEO Dave Mosley sold 20,000 shares on Feb. 2 under a pre-arranged plan, SEC filings show. U.S. jobs and inflation data next week are seen as key tests for tech stocks.
Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

7 February 2026
Cummins shares jumped 6.8% to $577.73 Friday, recovering from a nearly 9% post-earnings drop the day before. The company reported Q4 revenue up 1% to $8.54 billion, took a $218 million charge tied to its hydrogen business, and guided for 2026 EBITDA of 17–18% of sales. Demand for data center generators offset weakness in North American truck markets. Analyst reaction was mixed; Truist raised its price target.
Corning stock hits first record close since 2000 as jobs, CPI data loom

Corning stock hits first record close since 2000 as jobs, CPI data loom

7 February 2026
Corning shares surged 8.3% to $122.16 Friday, their highest close since the dot-com era, after Meta agreed to buy up to $6 billion in fiber-optic cables. The stock is up 40% since late 2025, fueled by strong first-quarter guidance and AI data-center demand. Insiders sold shares following the rally, SEC filings show. Investors await next week’s U.S. jobs and inflation data for rate signals.
Go toTop